201February, the company was rated as one of the top 50 enterprises in Beijing Economic and Technological Development Zone with 201/tax increase.
201February, the company and its wholly-owned subsidiary, Shutaishen New Drug, successfully passed the review of 20 1 1 high-tech enterprise, and obtained the high-tech enterprise certificate jointly issued by Beijing Science and Technology Commission, Beijing Finance Bureau, Beijing State Taxation Bureau and Beijing Local Taxation Bureau.
On 20 12 0 10, the company obtained the special financial fund of Beijing high-tech achievement transformation project.
20 1 1 year 1 1 month, the company was approved as the second batch of "100,000 projects" to cultivate key enterprises in Zhongguancun National Independent Innovation Demonstration Zone.
On February 20 10, the company completed the renewal of the Pharmaceutical Production License and obtained a new license valid until February 20 15.
20 10- 10, after qualification examination, expert evaluation, evaluation by the preparatory group of "Promoting the Implementation of the Strategic Mobilization Conference for Strengthening Science and Technology Zones" of Beijing Economic and Technological Development Zone Management Committee, and approval by the director's office meeting, the company was selected as "the advanced unit of scientific and technological innovation in Beijing Economic and Technological Development Zone".
On August 20 10, the company's "Shutaishen Pharmaceutical Industry Base" project passed the joint audit of the National Development and Reform Commission and the Economic and Information Technology Commission, and was included in the "Special Project for Revitalization and Technical Transformation of Key Industries".
20 10 In June, two R&D projects with Su Taisheng, the company's main product, as the core were selected as "National Twelfth Five-Year Major New Drug Creation Projects".
From June, 5438 to February, 2009, the company was jointly evaluated by Beijing Municipal People's Government, Ministry of Science and Technology and China Academy of Sciences as "innovative pilot enterprise in Zhongguancun National Independent Innovation Demonstration Zone".
From June, 5438 to February, 2009, the project of "Rat Nerve Growth Factor for Injection" won the third prize of Beijing Science and Technology Progress Award.
In September, 2009, the company's main products-Rat Nerve Growth Factor for Injection "Sutaisheng" and Polyethylene Glycol Electrolyte Powder "Shutaiqing" were recognized as "Beijing Independent Innovation Products". In August 2009, the company was recognized as a high-tech enterprise in Zhongguancun by the Zhongguancun Science Park Management Committee.
In June 2009, the company's "Su Taisheng Upgrade Product Phase I R&D" project was supported by the special fund for scientific and technological innovation of Beijing Economic and Technological Development Zone in 2008, with a price of 1.8 million yuan.
In July 2009, the company's Zhongguancun Enterprise Credit Report (Depth) was rated as ZCA credit rating and became a member of Beijing Zhongguancun Enterprise Credit Promotion Association.
In March, 2009, trospium chloride API and trospium chloride Capsule developed by the company obtained new drug certificates.
From June 5438 to February 2008, the company was jointly recognized as a high-tech enterprise in Beijing by Beijing Science and Technology Commission, Beijing Finance Bureau, Beijing State Taxation Bureau and Beijing Local Taxation Bureau.